Abstract
Nanite has netted $6 million in seed funding to launch its artificial intelligence platform for designing polymer nanoparticles for nonviral gene delivery. A drug’s delivery mechanism can be as important as the drug itself. For gene therapies, adeno-associated viruses (AAVs) are the most established delivery vehicle. But AAVs have a limited payload and can trigger an immune response. Lipid nanoparticles, which are used in COVID-19 messenger RNA vaccines , are an alternative delivery vehicle. But they tend to get stuck in the liver so aren’t suited for tissue-specific delivery. Polymer nanoparticles are the latest nonviral delivery alternatives. Their main advantage is their chemical diversity, says Sean Kevlahan, Nanite’s CEO and cofounder. Their resulting versatility allows scientists to tailor polymers for different cargo and tissue targets. The polymer capsule involves many design considerations, including the monomer chemistry, polymer architecture, and surface charge distribution. Nanite employs AI to predict the design for
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
